Rachid Izzar - Biogen Head Commercialization
| BIIB Stock | USD 160.85 3.38 2.06% |
Executive
Rachid Izzar is Head Commercialization of Biogen Inc
| Age | 49 |
| Address | 225 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.0499 % which means that it generated a profit of $0.0499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1047 %, meaning that it created $0.1047 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Roy Papatheodorou | Sanofi ADR | 46 | |
| Roopal MD | AbbVie Inc | 52 | |
| Ahmet Tezel | Johnson Johnson | N/A | |
| Johannes Oosthuizen | Merck Company | 56 | |
| David Redfern | GlaxoSmithKline PLC ADR | 58 | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
| Sloan Simpson | Novartis AG ADR | N/A | |
| Elizabeth JD | Johnson Johnson | 53 | |
| Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
| Scott Skellenger | Amgen Inc | N/A | |
| Arvind Sood | Amgen Inc | N/A | |
| Ahn Poole | Bristol Myers Squibb | 49 | |
| Linda Higgins | Gilead Sciences | 62 | |
| Alan Russell | Amgen Inc | N/A | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Shannon Klinger | Novartis AG ADR | 49 | |
| Francesca DeMartino | Pfizer Inc | N/A | |
| Sandra Esq | Bristol Myers Squibb | 63 | |
| Chirfi Guindo | Merck Company | 58 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| FranoisXavier Roger | Sanofi ADR | 62 | |
Management Performance
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0499 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO President | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Susan Esq, Executive Officer | ||
| Michael CPA, Executive CFO | ||
| Natacha Gassenbach, Chief Affairs | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Rachid Izzar, Head Commercialization | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Charles Triano, Senior Relations | ||
| Alisha Alaimo, President America | ||
| Adam Keeney, Executive Development | ||
| Stephen Amato, Head Relations |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0499 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 28.88 B | ||||
| Shares Outstanding | 145.72 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 92.96 % | ||||
| Number Of Shares Shorted | 2.7 M | ||||
| Price To Earning | 14.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.05 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.